VNRX Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 0.3%, SMA50 -9.6%, SMA200 -51.32%). The stock’s 14-day RSI is 48.19 (neutral), while the ATR of 0.03 points to moderate volatility. The stock remains hovering near 52-week lows, trading -74.84% below its high and over 39.12% above its low. Average 10-day trading volume of 218.93 thousand shares is below the 3-month average of 643.67 thousand, indicating normal recent market interest.

VolitionRx Limited has 107.59 million shares outstanding. The public float is 77.25 million shares, elevated short interest at 0.38% of float. This equals 298.50 thousand shares. The short ratio is 1.79 days. Institutional investors hold 19.76% of the float. Insiders own 13.55%. Reynolds Cameron John holds 2.55 million shares, Faulkes Martin Charles has 1.67 million shares and Micallef Jacob Vincent has 426.03 thousand shares.

VolitionRx Limited generated EPS of -$0.23 over the past year. Five-year average earnings growth is 5.38%. The latest quarter delivered EPS of -$0.97. The next quarter is forecast at -$0.04. Next year's EPS is expected at $20.27. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 17 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $5.00 to $1.00. The high target offers 85.19% upside. The low target suggests -62.96% downside. The mean target is $3.82. This offers 41.48% upside. VolitionRx Limited earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 14, 2026, missed forecasts by 38.57%. The prior quarter beat by 2400.0%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in March 31, 2025.

VolitionRx Limited (AMEX:VNRX) closed at $3.22 USD, gaining $0.52 (19.26%) from the previous close of $2.70. The stock is currently mid-range between its 52-week high and low $1.91 and $18.80. With a market capitalization of about $17.22 million, VolitionRx Limited is classified as a micro-cap and shows market-like volatility (beta ~1.03). Key stats such as the average daily volume over the past year has been around 609.27 thousand shares, in line with its 52-week average. Headquartered in Henderson, TX, VolitionRx Limited operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Cameron Reynolds, the company employs approximately 85 people and listed since March 02, 2012. VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide.

VolitionRx Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.37. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that VolitionRx Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -28.52%, with price expected at $1.93 by June 03, 2026, within a range of $1.72 to $2.13 3-Month Outlook: Projected fall of -2.59%, reaching $2.63 by August 19, 2026, with a range of $2.32 to $2.93. 1-Year Outlook: Projected loss of -91.11%, with price at $0.24 by May 21, 2027, within a range of $0.00 to $0.00.

VolitionRx Limited (AMEX:VNRX) shares are up 24.37% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows VolitionRx Limited trading at a premium to the broader market with a P/E of -0.76. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $4.82, suggesting 78.52% upside. Our AI forecast model points to short-term weakness (-28.52% over two weeks), a medium-term fall (-2.59% over three months), and a longer-term loss (-91.11% over one year), with expected trading ranges indicating moderate volatility.

VolitionRx Limited trades at a P/E ratio of -0.76, slightly below the S&P 500 average, with a price-to-sales ratio of 5.91 and a price-to-book ratio of -0.59 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.71, also below market averages.